SG11201807472TA - Amanitin conjugates - Google Patents
Amanitin conjugatesInfo
- Publication number
- SG11201807472TA SG11201807472TA SG11201807472TA SG11201807472TA SG11201807472TA SG 11201807472T A SG11201807472T A SG 11201807472TA SG 11201807472T A SG11201807472T A SG 11201807472TA SG 11201807472T A SG11201807472T A SG 11201807472TA SG 11201807472T A SG11201807472T A SG 11201807472TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- liehwiese
- hilffelsheim
- amatoxin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Steroid Compounds (AREA)
Abstract
bete-An40. Amenin 30.2105 40Y., W O 20 17 / 149077 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/149077 Al 8 September 2017 (08.09.2017) WIPO I PCT (51) International Patent Classification: A61K 47/68 (2017.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/EP2017/054911 (22) International Filing Date: 2 March 2017 (02.03.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 16000511.2 3 March 2016 (03.03.2016) EP (71) Applicant: HEIDELBERG PHARMA GMBH [DE/DE]; Schriesheimer Strasse 101, 68526 Ladenburg (DE). (72) Inventors: LUTZ, Christian; Am Feldrain 36, 69469 Weinheim (DE). ANDERL, Jan; Fichtenstrasse 7, 64397 Modautal (DE). MULLER, Christoph; Mumbacher Str. 38, 69488 Birkenau (DE). SIMON, Werner; In der Liehwiese 29, 55595 Hilffelsheim (DE). WERNER-SI- MON, Susanne; In der Liehwiese 29, 55595 Hilffelsheim (DE). HECHLER, Torsten; Milhlbergweg 24, 64686 Lautertal (DE). KULKE, Michael; Egellstrasse 17, 67071 Ludwigshafen (DE). (74) Agent: WALLINGER RICKER SCHLOTTER TOST- MANN PATENT- UND RECHTSANWALTE, PART- NERSCHAFT MBB; Dr. Mathias Ricker, Zweibriicken- strasse 5-7, 80331 Munich (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: AMANITIN CONJUGATES FIGURE 7 (57) : The invention relates to a conjugate comprising (a) an amatoxin comprising (i) an amino acid 4 with a 6'-deoxy posi- tion; and (ii) an amino acid 8 with an S-deoxy position; (b) a target-binding moiety; and (c) optionally a linker linking said amatoxin and said target-binding moiety. The invention furthermore relates to a pharmaceutical composition comprising such conjugate. 11111111111111011101111111111101011111011101011111111011111111111111111111111110111111
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16000511.2A EP3222292A1 (en) | 2016-03-03 | 2016-03-03 | Amanitin conjugates |
PCT/EP2017/054911 WO2017149077A1 (en) | 2016-03-03 | 2017-03-02 | Amanitin conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201807472TA true SG11201807472TA (en) | 2018-09-27 |
Family
ID=55456549
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201807472TA SG11201807472TA (en) | 2016-03-03 | 2017-03-02 | Amanitin conjugates |
SG10201913942SA SG10201913942SA (en) | 2016-03-03 | 2017-03-02 | Amanitin conjugates |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913942SA SG10201913942SA (en) | 2016-03-03 | 2017-03-02 | Amanitin conjugates |
Country Status (25)
Country | Link |
---|---|
US (2) | US11590238B2 (en) |
EP (2) | EP3222292A1 (en) |
JP (2) | JP7084313B2 (en) |
KR (1) | KR102466933B1 (en) |
CN (1) | CN108778341B (en) |
AU (1) | AU2017228020A1 (en) |
BR (1) | BR112018067615A2 (en) |
CA (1) | CA3015138A1 (en) |
CL (1) | CL2018002502A1 (en) |
CO (1) | CO2018009533A2 (en) |
DK (1) | DK3423104T5 (en) |
ES (1) | ES2925006T3 (en) |
HR (1) | HRP20220948T1 (en) |
HU (1) | HUE059360T2 (en) |
LT (1) | LT3423104T (en) |
MX (1) | MX2018010247A (en) |
NZ (1) | NZ745508A (en) |
PL (1) | PL3423104T3 (en) |
PT (1) | PT3423104T (en) |
RS (1) | RS63451B1 (en) |
RU (1) | RU2753416C2 (en) |
SG (2) | SG11201807472TA (en) |
SI (1) | SI3423104T1 (en) |
WO (1) | WO2017149077A1 (en) |
ZA (1) | ZA201805336B (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017204139B2 (en) | 2016-06-17 | 2018-08-09 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cells |
MX2019007604A (en) | 2016-12-23 | 2019-08-16 | Heidelberg Pharma Res Gmbh | Amanitin antibody conjugates. |
US10576161B2 (en) | 2017-01-20 | 2020-03-03 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD137+ cells |
EP3738608A4 (en) * | 2017-08-18 | 2021-12-08 | Sichuan Baili Pharm Co. Ltd | Non-natural amatoxin-type antibody conjugate |
KR20190043031A (en) * | 2017-10-17 | 2019-04-25 | 한국화학연구원 | Amatoxin derivatives and methods for their preparation |
EP3703676A4 (en) * | 2017-11-04 | 2021-12-15 | Advanced Proteome Therapeutics, Inc. | Composition and method for modifying polypeptides |
EP3740233A4 (en) * | 2018-01-18 | 2021-11-24 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd134+ cells |
WO2019197654A1 (en) * | 2018-04-13 | 2019-10-17 | Heidelberg Pharma Research Gmbh | Targeted amatoxin conjugate for the treatment of solid tumors |
CA3101943A1 (en) * | 2018-06-07 | 2019-12-12 | Magenta Therapeutics, Inc. | Therapeutic methods using antibody drug conjugates (adcs) |
EP3826626A4 (en) * | 2018-07-23 | 2022-07-06 | Magenta Therapeutics, Inc. | Use of anti-cd137 antibody drug conjugate (adc) in allogeneic cell therapy |
WO2020127968A1 (en) | 2018-12-20 | 2020-06-25 | Marino Stephen F | Protein-drug conjugate comprising a monomeric form of proteinase 3 |
MX2021012961A (en) | 2019-04-24 | 2021-11-25 | Heidelberg Pharma Res Gmbh | Amatoxin antibody-drug conjugates and uses thereof. |
JP2022533430A (en) | 2019-05-23 | 2022-07-22 | ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング | Antibody drug conjugates with cleavable linkers |
CN114080395A (en) * | 2019-07-05 | 2022-02-22 | 纯生物有机有限公司 | Synthesis method of alpha-amanitine and derivatives thereof |
EP3792250A1 (en) * | 2019-09-13 | 2021-03-17 | Pure Bioorganics SIA | Synthesis of alpha-amanitin and its derivatives |
AR120218A1 (en) * | 2019-10-15 | 2022-02-02 | Heidelberg Pharma Res Gmbh | AMATOXIN AND B LYMPHOCYTE SPECIFIC ANTIBODY CONJUGATES |
EP4161946A1 (en) * | 2020-06-09 | 2023-04-12 | Heidelberg Pharma Research GmbH | Method for synthesis of thioether-containing peptides |
EP4240424A1 (en) | 2020-11-04 | 2023-09-13 | Heidelberg Pharma Research GmbH | Composition comprising a combination of immune checkpoint inhibitor and antibody-amatoxin conjugate for use in cancer therapy |
JPWO2022138598A1 (en) * | 2020-12-22 | 2022-06-30 | ||
JP2024512478A (en) | 2021-03-19 | 2024-03-19 | ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング | B lymphocyte-specific amatoxin antibody conjugate |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69120146T2 (en) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | GENERATION OF XENOGENIC ANTIBODIES |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US6613879B1 (en) | 1999-05-14 | 2003-09-02 | Boehringer Ingelheim Pharma Kg | FAP-activated anti-tumour compounds |
ATE521366T1 (en) | 2006-05-27 | 2011-09-15 | Faulstich Heinz Dr | APPLICATION OF AMATOXIN CONJUGATES AND PHALLOTOXIN CONJUGATES WITH MACROMOLECLES FOR CANCER THERAPY AND THERAPY OF INFLAMMATION |
CL2009000505A1 (en) | 2008-03-05 | 2010-01-15 | Biocryst Pharm Inc | Compounds derived from nitrogenous tricycles, inhibitors of viral DNA and RNA polymerases; pharmaceutical composition comprising them; and use in the treatment of viral infections and cancer. |
TW200942243A (en) | 2008-03-05 | 2009-10-16 | Biocryst Pharm Inc | Antiviral therapeutic agents |
LT3192529T (en) | 2009-04-08 | 2020-06-25 | Faulstich, Heinz, Dr. | Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy |
KR20110140124A (en) | 2009-04-08 | 2011-12-30 | 하인즈 파울스티히 | Amatoxin-armed target-binding moieties for the treatment of cancer |
CA2770617C (en) | 2009-08-10 | 2018-02-20 | Mark Smith | Reversible covalent linkage of functional molecules |
KR101738203B1 (en) | 2010-04-15 | 2017-05-19 | 메디뮨 리미티드 | Pyrrolobenzodiazepines and conjugates thereof |
EP2436398B1 (en) | 2010-09-30 | 2013-01-23 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkers |
EP2497499A1 (en) | 2011-03-10 | 2012-09-12 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkages |
ES2703540T3 (en) | 2012-06-04 | 2019-03-11 | Novartis Ag | Site-specific marking methods and molecules produced in this way |
EP2684865A1 (en) | 2012-07-13 | 2014-01-15 | Heidelberg Pharma GmbH | Methods for synthesizing amatoxin building block and amatoxins |
MA37975B2 (en) | 2012-09-11 | 2021-03-31 | Genzyme Corp | Glucosylceramide synthase inhibitors |
PT3366705T (en) | 2012-09-12 | 2023-07-19 | Genzyme Corp | Fc containing polypeptides with altered glycosylation and reduced effector function |
US20150218220A1 (en) * | 2012-09-12 | 2015-08-06 | Brian Alan MENDELSOHN | Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase |
JP6321687B2 (en) * | 2014-03-10 | 2018-05-09 | ハイデルベルク ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング | Amatoxin derivatives |
PL3268047T3 (en) * | 2015-03-09 | 2024-03-18 | Heidelberg Pharma Research Gmbh | Amatoxin-antibody conjugates |
US11166912B2 (en) | 2016-03-03 | 2021-11-09 | Ctt Pharma Inc. | Orally administrable composition |
-
2016
- 2016-03-03 EP EP16000511.2A patent/EP3222292A1/en not_active Withdrawn
-
2017
- 2017-03-02 JP JP2018546006A patent/JP7084313B2/en active Active
- 2017-03-02 EP EP17707350.9A patent/EP3423104B1/en active Active
- 2017-03-02 MX MX2018010247A patent/MX2018010247A/en unknown
- 2017-03-02 DK DK17707350.9T patent/DK3423104T5/en active
- 2017-03-02 ES ES17707350T patent/ES2925006T3/en active Active
- 2017-03-02 CO CONC2018/0009533A patent/CO2018009533A2/en unknown
- 2017-03-02 SG SG11201807472TA patent/SG11201807472TA/en unknown
- 2017-03-02 CN CN201780014892.2A patent/CN108778341B/en active Active
- 2017-03-02 RS RS20220709A patent/RS63451B1/en unknown
- 2017-03-02 SI SI201731197T patent/SI3423104T1/en unknown
- 2017-03-02 KR KR1020187027424A patent/KR102466933B1/en active IP Right Grant
- 2017-03-02 HU HUE17707350A patent/HUE059360T2/en unknown
- 2017-03-02 CA CA3015138A patent/CA3015138A1/en active Pending
- 2017-03-02 LT LTEPPCT/EP2017/054911T patent/LT3423104T/en unknown
- 2017-03-02 NZ NZ745508A patent/NZ745508A/en unknown
- 2017-03-02 WO PCT/EP2017/054911 patent/WO2017149077A1/en active Application Filing
- 2017-03-02 BR BR112018067615A patent/BR112018067615A2/en active Search and Examination
- 2017-03-02 AU AU2017228020A patent/AU2017228020A1/en active Pending
- 2017-03-02 US US16/081,400 patent/US11590238B2/en active Active
- 2017-03-02 PT PT177073509T patent/PT3423104T/en unknown
- 2017-03-02 SG SG10201913942SA patent/SG10201913942SA/en unknown
- 2017-03-02 PL PL17707350.9T patent/PL3423104T3/en unknown
- 2017-03-02 HR HRP20220948TT patent/HRP20220948T1/en unknown
- 2017-03-02 RU RU2018131636A patent/RU2753416C2/en active
-
2018
- 2018-08-10 ZA ZA2018/05336A patent/ZA201805336B/en unknown
- 2018-08-31 CL CL2018002502A patent/CL2018002502A1/en unknown
-
2021
- 2021-11-08 JP JP2021182011A patent/JP7362714B2/en active Active
-
2023
- 2023-02-27 US US18/175,148 patent/US20230233703A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201807472TA (en) | Amanitin conjugates | |
SG11201908740VA (en) | Sustained release delivery systems comprising traceless linkers | |
SG11201811151PA (en) | Extracellular vesicle comprising a fusion protein having fc binding capacity | |
SG11201900619XA (en) | Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors | |
SG11201908540PA (en) | Stable antibody formulation | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
SG11201907034PA (en) | Methods of treating influenza | |
SG11201808710UA (en) | Novel immunogenic cd1d binding peptides | |
SG11201906744VA (en) | Core/shell structure platform for immunotherapy | |
SG11201909303TA (en) | Point of delivery cold slurry generation | |
SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
SG11201810177VA (en) | Pet-imaging immunomodulators | |
SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
SG11201810429UA (en) | Anti-cd19 antibody formulations | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201811209QA (en) | Oral gastroretentive formulations and uses thereof | |
SG11201908660RA (en) | N-substituted indole derivatives | |
SG11201903431SA (en) | Sstr-targeted conjugates and particles and formulations thereof | |
SG11201902567WA (en) | Expec glycoconjugate vaccine formulations | |
SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
SG11201907693VA (en) | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | |
SG11202000494UA (en) | Drug delivery composition | |
SG11201900336YA (en) | Radioligands for imaging the ido1 enzyme | |
SG11201811804QA (en) | Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors |